Symbols

VCEL

Vericel·NASDAQ

--(--)

VCEL fundamentals

VCEL Q4 2025 Earnings

Vericel (VCEL) released its earnings on Feb 26, 2026: revenue was 92.92M (YoY +23.27%), beat estimates; EPS was 0.45 (YoY +18.42%), beat estimates.

Revenue / YoY

92.92M

+23.27%

EPS / YoY

0.45

+18.42%

Report date

Feb 26, 2026

VCEL Earnings Call Summary for Q4,2025

Record Q4 Growth: Total revenue $92.9 million (+23% YoY), MACI $84.1 million (+23% YoY), and 79% gross margin.
Strategic Expansion: 30% MACI sales force increase, MACI Arthro adoption by 1,000 surgeons, and U.K. launch in 2027.
2026 Outlook: $316-$326 million revenue target, 75% gross margin, and $220 million OpEx.
Key Drivers: MACI Arthro for small condyle defects, Ankle MASCOT trial, and U.S. sales force productivity recovery.
Financial Strength: $200 million cash, 59% YoY net income growth, and $52 million operating cash flow.

Earnings

EPS

Revenue

Revenue & Expenses

VCEL has released its 2025 Q4 earnings report, with revenue of 92.92M, reflecting a YoY change of 23.27%, and net profit of 23.24M, showing a YoY change of 17.35%. The Sankey diagram below clearly presents VCEL's revenue sources and cost distribution.

Key Indicators

Vericel (VCEL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Vericel (VCEL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Vericel (VCEL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Vericel (VCEL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown